ICU Medical, Inc. ICUI
164.95
(1.07)
(0.64%)
as of 25 Sep
- Market cap
- $4.2B
- P/E
- 137×
Follow ICUI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 7,133.50 | 69.06 | 122.17 |
P/S ratio |
1.28 | 1.58 | 1.48 | 1.70 | |
P/FCF ratio |
47.51 | 38.68 | 38.97 | 23.97 | |
P/Operating CF |
52.22 | 58.01 | 82.20 | 45.73 | |
P/B ratio |
1.39 | 1.66 | 1.51 | 1.70 | |
Price to Tangible BV |
0.00 | 0.00 | 116.73 | 36.72 | |
EV/Sales |
1.73 | 2.01 | 1.94 | 2.13 | |
EV/EBITDA |
14.14 | 17.99 | 16.76 | 16.56 | |
EV/Operating CF |
25.23 | 24.98 | 25.03 | 19.45 | |
EV/FCF |
64.55 | 49.42 | 51.06 | 30.07 | |
Quick Ratio |
1.00 | 0.98 | 0.95 | 0.97 | |
Current Ratio |
2.45 | 2.39 | 2.34 | 2.43 | |
Net Debt/EBITDA |
15.33 | 16.98 | 15.41 | 10.42 | |
Debt/Assets |
32.02% | 31.72% | 31.90% | 31.00% | |
Debt/Equity |
0.62 | 0.60 | 0.61 | 0.57 | |
Asset Turnover |
0.55 | 0.54 | 0.53 | 0.53 | |
Operating CF/Net income |
(16.70) | (3.85) | 1.29 | 4.20 | |
Capex/Depreciation |
(0.61) | (0.35) | (0.26) | (0.40) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
3.96% | 3.90% | 4.01% | 4.12% | |
Selling, General and Administrative Expense of Revenue |
28.45% | 28.82% | 29.15% | 27.54% | |
Intangible Assets out of Total Assets |
0.53 | 0.53 | 0.52 | 0.52 | |
Share Based Compensation of Revenue |
2.84% | 2.57% | 2.64% | 2.15% | |
Graham Net Nets |
(0.26) | (0.21) | (0.22) | (0.17) | |
Graham Number |
0.00 | 6.23 | 59.90 | 48.21 | |
Earnings Yield |
(0.26%) | 0.01% | 1.45% | 0.82% | |
Free Cash Flow Yield |
2.10% | 2.59% | 2.57% | 4.17% | |
Revenue per Share |
21.75 | 21.94 | 21.41 | 22.07 | |
Operating CF per Share |
2.30 | 2.46 | 1.57 | 3.21 | |
Capex per Share |
(1.29) | (0.75) | (0.53) | (0.81) | |
Free Cash Flow per Share |
1.01 | 1.71 | 1.04 | 2.40 | |
Cash per Share |
12.14 | 12.50 | 11.64 | 11.93 | |
Shareholders Equity per Share |
86.17 | 86.19 | 85.28 | 86.07 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
86.17 | 86.19 | 85.28 | 86.07 | |
Free Cash Flow |
24.96 | 42.21 | 25.70 | 60.01 | |
Working Capital |
714.39 | 691.69 | 695.34 | 712.54 | |
Capital Expenditures |
(31.75) | (18.39) | (13.21) | (20.14) | |
Net Current Asset Value |
(768.36) | (736.13) | (688.59) | (608.52) | |
EV/EBIT |
53.73 | 104.88 | 96.29 | 63.81 | |
Capex to Sales |
0.06 | 0.03 | 0.02 | 0.04 | |
Net Profit Margin |
(0.63%) | (2.91%) | 5.68% | 3.46% | |
Price to Operating Income |
39.55 | 82.08 | 73.49 | 50.86 | |
| Other line items | |||||
Average Receivables |
182.76 | 181.67 | 186.00 | 181.51 | |
Average Payables |
170.16 | 151.20 | 177.20 | 158.99 | |
Average Inventory |
657.24 | 600.27 | 597.96 | 611.95 | |
Average Assets |
4,203.97 | 4,127.22 | 4,099.17 | 4,039.34 | |
Average Common Equity |
2,087.92 | 2,044.53 | 2,049.81 | 2,133.81 |
Columns are period end dates